[1] Gilissen C, Hehir-Kwa JY, Thung DT, et al. Genome sequencing identifies major causes of severe intellectual disability[J]. Nature, 2014, 511(7509):344-347. [2] Deciphering Developmental Disorders Study.Large-scale discovery of novel genetic causes of developmental disorders[J]. Nature, 2015, 519(7542):223-228. [3] Houge G, Haesen D, Vissers L, et al. B56δ-related protein phosphatase 2A dysfunction identified in patients with intellectual disability[J]. J Clin Invest, 2015, 125(8):3051-3062. [4] Lenaerts L, Reynhout S, Verbinnen I, et al. The broad phenotypic spectrum of PPP2R1A-related neurodevelopmental disorders correlates with the degree of biochemical dysfunction[J]. Genet Med, 2021,23(2):352-362. [5] Wallace A, Caruso P, Karaa A. A newborn with severe ventriculomegaly:Expanding the PPP2R1A gene mutation phenotype[J]. J Pediatr Genet, 2019, 8(4):240-243. [6] Zhang Y, Li H, Wang H, et al. A De Novo Variant identified in the PPP2R1A gene in an infant induces neurodevelopmental abnormalities[J]. Neurosci Bull, 2020, 36(2):179-182. [7] Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015,17(5):405-424. [8] Janssens V, Goris J. Protein phosphatase 2A: A highly regulated family of serine/threonine phosphatases implicated in cell growth and signaling[J]. Biochem J, 2001, 353(Pt 3):417-439. [9] Reynhout S, Janssens V. Physiologic functions of PP2A: Lessons from genetically modified mice[J].Biochim Biophys Acta Mol Cell Res, 2019, 1866(1):31-50. [10] Sents W, Ivanova E, Lambrecht C, et al. The biogenesis of active protein phosphatase 2A holoenzymes: A tightly regulated process creating phosphatase specificity[J]. Febs J,2013,280(2):644-661. [11] McConechy MK, Anglesio MS,Kalloger SE, et al. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas[J]. J Pathol, 2011, 223(5):567-573. [12] Shih IM, Panuganti PK, Kuo KT, et al. Somatic mutations of PPP2R1A in ovarian and uterine carcinomas[J]. Am J Pathol, 2011, 178(4):1442-1447. [13] Jeong AL, Han S, Lee S, et al. Patient derived mutation W257G of PPP2R1A enhances cancer cell migration through SRC-JNK-c-Jun pathway[J]. Sci Rep, 2016,6:27391. [14] Taylor SE, O'Connor CM, Wang Z, et al. The highly recurrent PP2A Aα subunit mutation P179R alters protein structure and impairs PP2A enzyme function to promote endometrial tumorigenesis[J]. Cancer Res, 2019,79(16):4242-4257. [15] O'Connor CM, Leonard D, Wiredja D, et al. Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors[J]. Oncogene. 2020;39(3):703-717. [16] Haesen D, Asbagh L A, Derua R,et al.Recurrent PPP2R1A mutations in uterine cancer act through a dominant-negative mechanism to promote malignant cell growth [J]. Cancer Res, 2016, 76(19):5719-5731. [17] Verbinnen I, Vaneynde P, Reynhout S, et al. Protein Phosphatase 2A (PP2A) mutations in brain function, development, and neurologic disease [J].Biochem Soc Trans, 2021, 49(4):1567-1588. [18] Brinkmann V, Billich A, Baumruker T, et al.Fingolimod (FTY720): Discovery and development of an oral drug to treat multiple sclerosis [J]. Nat Rev Drug Discov, 2010, 9(11):883-897. [19] Clark AR, Ohlmeyer M.Protein phosphatase 2A as a therapeutic target in inflammation and neurodegeneration [J]. Pharmacol Ther, 2019, 201:181-201. [20] Gutierrez A, Pan L, RGroen R W J, et al. Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia[J]. J Clin Invest, 2014, 124(2):644-655. |